Zura Bio Limited (ZURA)

Market Cap	442.82M +294.3%
Revenue (ttm)	n/a
Net Income	-62.52M
EPS	-0.67
Shares Out	73.68M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	452,142
Open	5.72
Previous Close	5.67
Day's Range	5.59 - 6.11
52-Week Range	0.97 - 6.63
Beta	0.21
Analysts	Strong Buy
Price Target	11.38 (+89.35%)
Earnings Date	Mar 24, 2026

About ZURA

Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for immune and inflammatory disorders in the United States. The company develops Tibulizumab, an immunoglobulin G-single-chain variable fragment bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes interleukin (IL)-17A and B-cell activating factor, which is in Phase 2 clinical trial development. It is also developing Torudokimab (ZB-880), a monoclonal antibody that neutralizes IL-33 to prevent ST2-dependent and ST2-i...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2022
• Employees: 30
• Stock Exchange: NASDAQ
• Ticker Symbol: ZURA
• Website: https://zurabio.com

Analyst Summary

According to 8 analysts, the average rating for ZURA stock is "Strong Buy." The 12-month stock price target is $11.38, which is an increase of 89.35% from the latest price.

Price Target

$11.38

(89.35% upside)

Analyst Consensus: Strong Buy